Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Law

UK government plans to ban psychoactive drugs

A bill was announced in the Queen’s speech that would ban production and supply of psychoactive drugs in the UK.

Synthetic marijuana known as spice

Source: Eric Engman/Fairbanks Daily News-Miner/ZUMAPRESS.com) / Alamy.com

The UK government wants to protect young people from the dangers of ‘legal highs’ and plans to ban all psychoactive drugs

The UK government is introducing a bill that would bring a blanket ban on the production and supply of any drug that has a psychoactive effect in an effort to crack down on a wave of new recreational drugs.

The government wants to protect young people from the dangers of so-called ‘legal highs’ and target those who profit from these products, but some scientists have warned that the move could inhibit research into potentially useful new substances.

The plans, which aim to ban the “new generation of psychoactive drugs”, were announced in the Queen’s speech on 27 May 2015. The bill is so wide-reaching that products such as alcohol, tobacco, caffeine and certain medicines will be given a special exemption from the ban.

“The landmark bill will fundamentally change the way we tackle new psychoactive substances — and put an end to the game of cat and mouse in which new drugs appear on the market more quickly than government can identify and ban them,” says Mike Penning, the minister for policing, crime, criminal justice and victims.

In recent years there has been a wave of previously unseen drugs being used recreationally, with the government banning more than 500 new drugs. These include synthetic cannabinoids, the amphetamine mephedrone and gamma hydroxybutyrate (GHB), a central nervous system depressant.

An increasing number of deaths have been blamed on these substances; in 2013, there were 120 deaths involving new psychoactive substances in England, Scotland and Wales. In Scotland, there were 60 deaths in 2013 in which a new psychoactive substance was implicated, but for 55 of these deaths other substances were also implicated. However, these statistics have been described as misleading because many of the drugs classed as “new” or “legal” are already banned and/or have been around for some time. For example, in 2013 the ‘new psychoactive substance’ most often implicated in these deaths was phenazepam, a strong benzodiazepine used in Russia as a medicine since the mid-1970s, which was banned in the UK in June 2012.

And deaths involving p-methoxyamphetamine (PMA) are also included in these statistics, despite the fact it has been controlled in the UK since 1977.

Under the Psychoactive Substances Bill, the supply, production, import or export of any psychoactive substance, without an exemption, will carry a maximum term of seven years in prison.

However, the ban has been condemned by David Nutt, chair of Drug Science, a science-led drugs charity, which he set up after he was controversially fired in 2009 as chair of the government’s Advisory Council on the Misuse of Drugs. Nutt argues that considering many of the drugs implicated in deaths attributed to “legal highs” are in fact already illegal, a further ban will make no difference.

He argues that a ban may lead to more deaths as it could cause supplies to be forced underground resulting in drugs of “uncertain provenance”. Instead, he advocates that the UK follows the Dutch model. The Netherlands has brought in national drugs testing facilities that allow users to find out if their drugs are pure or contaminated. “They have virtually eliminated deaths from new psychoactive substances,” says Nutt.

He also suggests the ban will affect the UK pharmaceutical industry and have a “serious unplanned impact” on research into new brain drugs. For example, he asks whether new antidepressant and anti-epilepsy drugs that are being studied now, or are yet to be discovered, could fall ‎under the ban.

The Home Office has assured that this will not be the case. It says all medicines and medicines in development will be exempt and no extra licenses will be needed for clinical trials of psychoactive drugs.

The bill was put before parliament on 29 May 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068637

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.